NBIL:NASDAQGraniteShares 2x Long NBIS Daily ETF Analysis
Data as of 2026-07-05 - not real-time
$33.16
Latest Price
9/10Risk
Risk Level: High
Executive Summary
The ETF has delivered an eye‑catching 384% YTD return, but that performance is built on a 2x daily leverage structure that amplifies both gains and losses. At the latest close the price sits at $33.16, well under the 20‑day SMA of $47.96 and the 50‑day SMA of $38.75, indicating a short‑term pullback. The technical support level aligns with today’s low at $30.40, while the 52‑week resistance sits near $68.49, a gap that would require a sustained rally to close. A 30‑day volatility reading of 231% and a beta of 6.6 signal extreme price swings relative to the broader market. The market sentiment gauge is in the Extreme Greed zone at 93.2, suggesting that speculative enthusiasm may be inflating price moves.
The RSI of 41 places the ETF in a modestly oversold region, offering a hint of upside potential if buying pressure returns. Conversely, the MACD histogram is negative and the signal line is bearish, pointing to lingering downside momentum. The fund’s expense ratio of 1.5% is higher than traditional ETFs, further eroding returns over time. Leveraged daily products typically suffer from decay when held beyond a few days, a risk underscored by the historical max drawdown of ‑78%. Liquidity appears adequate with stable volume around 3.5 M shares, yet the combination of high beta and leverage keeps overall risk very high. Given these dynamics, the short‑term view leans toward a hold stance while monitoring the support level and sentiment. For medium and long horizons, the structural risks of leverage and sector concentration advise selling or avoiding the position.
The RSI of 41 places the ETF in a modestly oversold region, offering a hint of upside potential if buying pressure returns. Conversely, the MACD histogram is negative and the signal line is bearish, pointing to lingering downside momentum. The fund’s expense ratio of 1.5% is higher than traditional ETFs, further eroding returns over time. Leveraged daily products typically suffer from decay when held beyond a few days, a risk underscored by the historical max drawdown of ‑78%. Liquidity appears adequate with stable volume around 3.5 M shares, yet the combination of high beta and leverage keeps overall risk very high. Given these dynamics, the short‑term view leans toward a hold stance while monitoring the support level and sentiment. For medium and long horizons, the structural risks of leverage and sector concentration advise selling or avoiding the position.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Price hovering at support around $30.40
- RSI indicating modest oversold condition
- Extreme market greed signal
Medium Term
1–3 yearsCautious
Model confidence: 7/10
Key Factors
- Leverage decay risk over multiple days
- Negative MACD momentum
- High beta and volatility
Long Term
> 3 yearsCautious
Model confidence: 8/10
Key Factors
- Structural 2x daily leverage unsuitable for long holding
- Sector concentration in biotech
- Elevated expense ratio and max drawdown history
Key Metrics & Analysis
Fund Metrics
Expense Ratio1.50%
AUM$150.4M
Inception Date2025-10-06
Avg Daily Volume1,827,720
Premium/Discount0.00%
Tracking Error0.00%
Technical Analysis
TrendBullish
RSI41.4
Support$30.40
Resistance$68.49
MA 20$47.96
MA 50$38.75
MA 200$20.70
MACDBearish
VolumeStable
Fear & Greed Index93.2
Risk Assessment
Beta6.60
Volatility231.81%
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.